# Evaluation of Safety and Immunogenicity of the Recombinant ZR202-CoV and ZR202a-CoV Vaccines in Adults.

> **NCT05490108** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Shanghai Zerun Biotechnology Co.,Ltd** · enrollment: 60 (actual)

## Conditions studied

- SARS-CoV-2 Infection
- COVID-19

## Interventions

- **BIOLOGICAL:** ZR202-CoV
- **BIOLOGICAL:** ZR202a-CoV
- **BIOLOGICAL:** Comirnaty®

## Key facts

- **NCT ID:** NCT05490108
- **Lead sponsor:** Shanghai Zerun Biotechnology Co.,Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-06-02
- **Primary completion:** 2022-09-26
- **Final completion:** 2023-08
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2023-04-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05490108

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05490108, "Evaluation of Safety and Immunogenicity of the Recombinant ZR202-CoV and ZR202a-CoV Vaccines in Adults.". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05490108. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*